Freedom of Information request about ecords of other patients who have experienced hearing loss with using Locorten Viaform ear drops with a perforated eardrum (FOI-21-422)
Published 28 June 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-10-may-2021/freedom-of-information-request-about-ecords-of-other-patients-who-have-experienced-hearing-loss-with-using-locorten-viaform-ear-drops-with-a-perforate
Thank you for your FOI request dated 13 th April 2021, where you requested the following information:
I would appreciate information on whether you have records of other patients who have experienced hearing loss with using Locorten Viaform ear drops with a perforated eardrum.
We can confirm that the MHRA does hold the requested information and it is publicly available via our interactive Drug Analysis Profiles (iDAP). A link to the relevant iDAP is provided below. This shows an overview of all UK spontaneous suspected Adverse Drug Reactions (ADRs) reported through the Yellow Card Scheme and under the term hearing loss, we have received 2 reports. https://info.mhra.gov.uk/drug-analysis-profiles/dap.html?drug=./UK_EXTERNAL/NONCOMBINED/UK_NON_000791216513.zip&agency=MHRA
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division